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ABSTRACT Homozygosity for the SERPINA1 Z allele causes α1-antitrypsin deficiency, a rare condition
that can cause lung and liver disease. However, the effects of Z allele heterozygosity on nonrespiratory
phenotypes, and on lung function in the general population, remain unclear.
We conducted a large, population-based study to determine Z allele effects on >2400 phenotypes in the
UK Biobank (N=303353).
Z allele heterozygosity was strongly associated with increased height (β=1.02 cm, p=3.91×10−68), and
with other nonrespiratory phenotypes including increased risk of gall bladder disease, reduced risk of heart
disease and lower blood pressure, reduced risk of osteoarthritis and reduced bone mineral density,
increased risk of headache and enlarged prostate, as well as with blood biomarkers of liver function.
Heterozygosity was associated with higher height-adjusted forced expiratory volume in 1 s (FEV1)
(β=19.36 mL, p=9.21×10−4) and FEV1/forced vital capacity (β=0.0031, p=1.22×10
−5) in nonsmokers,
whereas in smokers, this protective effect was abolished. Furthermore, we show for the first time that sex
modifies the association of the Z allele on lung function.
We conclude that Z allele heterozygosity and homozygosity exhibit opposing effects on lung function in
the UK population, and that these associations are modified by smoking and sex. In exploratory analyses,
heterozygosity for the Z allele also showed pleiotropic associations with nonrespiratory health-related traits
and disease risk.
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Heterozygosity for the SERPINA1 Z allele is associated with higher lung function in nonsmokers
(but this advantage is abolished by smoking) as well as a variety of nonrespiratory diseases and
traits, including liver-, heart- and bone-related conditions https://bit.ly/37XC0Yg
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Homozygosity for the SERPINA1 Z allele (rs28929474(T)) is the commonest cause of severe α1-antitrypsin
deficiency (AATD) and is a well-established genetic risk factor for lung diseases such as chronic
obstructive pulmonary disease (COPD). However, the health consequences of heterozygosity for the Z
allele are not as well-understood [1]. Given that approximately one in 30 Europeans is heterozygous for
the Z allele, the phenotypic consequences of carriage of this allele could have important public health
implications.
Some previous studies have sought to characterise the effect of Z allele heterozygosity on nonrespiratory
traits, particularly liver diseases [2–6]. However, these have often been carried out in small sample sizes
and/or clinical subgroups. The recent development of phenome-wide association studies (PheWASs) and
the availability of the well-phenotyped UK Biobank population-based cohort provides a platform for
systematic investigation of the effects of heterozygosity for the Z allele on nonrespiratory traits. PheWASs
test the association between genetic variants and a large number of phenotypic traits, including diseases
and their subtypes, and potential intermediate phenotypes [7]. This differs from genome-wide association
studies, which test a large number of variants across the genome for association with only one trait.
The effect of Z allele heterozygosity on lung function traits and lung disease has been the subject of many
studies. Recent COPD case–control and family-based studies have shown reduced lung function and
increased risk of COPD in heterozygous current and former smokers [8–11]. However, a population-based
study demonstrated no significant reductions in lung function in heterozygous smokers, despite having
greater numbers of heterozygous smokers compared to previous studies [12]. It also showed enhanced
lung function in heterozygous individuals overall, partially explained by strong association of the Z allele
with increased height. This discrepancy may be due, in part, to the fact that identifying and recruiting
study participants based on their health status (as in case–control studies [8, 9]) or based on the health
status of a family member [10, 11] can lead to causal estimates that are subject to ascertainment bias [13],
whereas population-based studies [12, 14] overcome these biases. The effects of the Z allele on lung
function in relation to smoking status therefore remain uncertain.
Finally, despite evidence for sex-differential effects of Z allele homozygosity on lung function [15, 16], we
are not aware of any studies that have compared the effect of Z allele heterozygosity on lung function in
males versus females.
We therefore systematically evaluated the effects of Z allele heterozygosity in the UK biobank population,
which in total includes >18000 Z allele heterozygotes. We aimed: 1) to undertake the most extensive
PheWAS to date, including blood biomarkers, for Z allele heterozygosity and homozygosity to identify
effects beyond the respiratory system; and 2) to fully define the effects of Z allele heterozygosity on lung
function measures (forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)) in smokers




This study used anonymised data from UK Biobank, which has ethical approval from the UK National
Health Service National Research Ethics Service (ref. 11/NW/0382). All participants provided written
informed consent. Ethical approval for the Avon Longitudinal Study of Parents and Children (ALSPAC)
was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.
Written informed consent for the use of data collected via questionnaires and clinics was obtained from
participants, parents or guardians following the recommendations of the ALSPAC Ethics and Law
Committee at the time.
UK Biobank
The UK Biobank data resource is described elsewhere (www.ukbiobank.ac.uk). Genotyping was undertaken
using the Affymetrix Axiom UK BiLEVE and UK Biobank arrays [17]. Genotypes were imputed based on
the Human Reference Consortium panel as described elsewhere [18]. Genotyping quality control was
performed as described previously [19]. UK Biobank individuals were selected for inclusion in PheWAS
analyses if they met the following criteria: 1) they had no missing data for sex or age; 2) they had
genome-wide imputed genetic data for rs28929474; 3) they were of genetically determined European
ancestry (see [19] for details); and 4) they were not first- or second-degree relatives. For lung function
analyses, individuals were additionally required to have spirometry data that passed quality control, as
described previously [19], and to have full data for height and smoking status as well as data derived from
direct genotyping for rs28929474 (N=303353).
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The Avon Longitudinal Study of Parents and Children
The ALSPAC cohort was invited to participate in this study after the main analyses in UK Biobank had
been completed, in order to explore the effects of the Z allele on height and lung function in younger age
groups. ALSPAC children were genotyped using the Illumina HumanHap550 quad genome-wide
single-nucleotide polymorphism genotyping platform (Illumina Inc., San Diego, CA, USA) by the
Wellcome Trust Sanger Institute (Cambridge, UK) and the Laboratory Corporation of America
(Burlington, NC, USA), using support from 23andMe. Further details of ALSPAC are available in the
supplementary material. Participants were excluded from this study if they had incorrectly recorded sex,
minimal or excessive heterozygosity, disproportionate levels of individual missingness (>3%), evidence of
cryptic relatedness or non-European ancestry.
Phenome-wide association studies
To identify whether SERPINA1 Z allele heterozygosity or homozygosity was associated with respiratory
and nonrespiratory traits and diseases, two PheWASs across all available traits were performed. The first
compared traits in individuals heterozygous for the Z allele versus wild type, and the second compared
individuals homozygous for the Z allele versus wild type and heterozygotes combined (recessive genetic
model). Up to 379101 individuals were available for these analyses. Traits included UK Biobank baseline
measures (from both questionnaires and physical measures), self-reported medication usage and operative
procedures, as well as those captured in Office of Population Censuses and Surveys codes from the
electronic health record. We also included self-reported disease variables and those from hospital episode
statistics (HES) (International Classification of Disease, 10th revision (ICD-10) codes truncated to
three-character codes, and combined in block and chapter groups) as well as combining both self-report
and hospital-diagnosed diseases, where possible, to maximise power. The analysis included 2411 traits
(traits with >200 cases were included [20]). Analyses were conducted in unrelated European-ancestry
individuals (KING kinship coefficient of <0.0442), and were adjusted for age, age2, sex, genotyping array
and 10 ancestry principal components (PCs). Logistic models were fitted for binary outcomes and linear
models were fitted for quantitative outcomes (rank transformed to normality). False discovery rates (FDRs)
were calculated according to the number of the traits in the analysis.
Statistical analyses for biomarkers, lung function, COPD and height
For continuous traits, linear regression models adjusted for sex, age, age2, the first 10 ancestry-based PCs
and genotyping array were tested in R. SERPINA1 Z genotype (derived from direct genotyping) was coded
according to the genetic model tested: either heterozygous (i.e. heterozygous versus wild type) or recessive.
For lung function analyses, ever-smoking status and standing height were also included in the models
unless indicated. To test for interaction of Z allele hetero- or homozygosity with ever-smoking status and
sex, interaction terms for sex and smoking were added to the model. Association testing with
moderate–severe COPD (defined as FEV1/FVC <0.7 and FEV1<80% predicted) or COPD of Global
Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1–4 (defined as FEV1/FVC <0.7) was
carried out using logistic regression in R adjusting for covariates sex, age, age2, ever-smoking status, height,
the first 10 ancestry-based PCs and genotyping array. In addition to the biomarkers available from UK
Biobank, we calculated estimated glomerular filtration rate (eGFR) using the following formula: if cystatin
C (cys)⩽0.8, then eGFR=133*((cys/0.8)**−0.499)*(0.996**age)*[0.932 if female]; whereas if cys>0.8, then
eGFR=133*((cys/0.8)**−1.328)*(0.996**age)*[0.932 if female].
In ALSPAC, the association of Z allele heterozygosity with height and lung function z-scores were
examined using linear regression models including age and gender (and including height in the lung
function analyses).
Polygenic risk scores
Polygenic risk scores for lower FEV1/FVC were generated in UK Biobank using Plink version 1.90b3.
These were based on 60730 autosomal variants with minor allele frequency >1% and p<0.05 (for the
association with FEV1/FVC in UK Biobank), and linkage disequilibrium pruned to r
2<0.1 in 250-kb
windows. Variants were weighted by FEV1/FVC β-coefficients from the SpiroMeta consortium cohorts [19].
Results
Frequency of the SERPINA1 Z in UK Biobank
Amongst 411002 unrelated, European UK Biobank participants with full sex, age, height, smoking status
and genotyping data, 16199 (3.94%) were heterozygous and 129 (0.0314%) were homozygous for the Z
allele. There were fewer ZZ homozygotes than expected under Hardy–Weinberg equilibrium in all samples
(p=0.004), ever-smokers (p=0.003), individuals >60 years of age (p=0.007) and females (p=0.007)
(table S1), consistent with reduced survival.
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PheWASs of the Z allele
To explore the effect of Z allele heterozygosity and homozygosity on a broad range of phenotypes, we
performed two PheWASs. The phenotypes most strongly associated with Z allele heterozygosity and Z
allele homozygosity (FDR <0.01) are shown in figure 1a and b respectively (full results are in tables S2 and
S3). Standing height, AATD and various respiratory phenotypes (lung function, reported emphysema,
chronic bronchitis and COPD) were strongly associated with the Z allele under either genetic model.
However, we also detected strong associations between Z allele heterozygosity and a number of other
phenotypes, including increased risk of gall stones (OR 1.35, p=1.69×10−16), gall bladder removal (OR
1.51, p=1.85×10−29) and bile duct disease (OR 1.25, p=5.42×10−8); cardiovascular phenotypes such as
lower risk of heart disease (OR 0.84, p=6.66×10−6) and family history of heart disease, and lower blood
pressure (p=1.02×10−10); musculoskeletal phenotypes such as a higher grip strength (p=5.67×10−7), lower
risk of osteoarthritis, particularly of knee or hip (OR 0.85, p=1.18×10−6), lower bone mineral density
(p=1.40×10−5) and higher risk of osteoporosis (OR 1.17, p=0.001); and higher risk of headache (OR 1.12,
p=5.66×10−9) and enlarged prostate (OR 1.26, p=1.95×10−7). The PheWAS also included blood counts for
a variety of different cell types, showing reduced reticulocytes in individuals heterozygous for the Z allele.
Z allele homozygosity was associated with increased haemoglobin (p=7.17×10−10), haematocrit
(p=6.17×10−8) and red blood cells (p=5.91×10−5), as well as optic neuritis (OR 26.9, p=4.32×10−6) and
pancreatitis (OR 6.07, p=7.76×10−5).
To extend these analyses to traits not previously available for the PheWAS, we investigated the effect of Z
allele heterozygosity and homozygosity on 30 key blood biochemistry markers in UK Biobank data
(table 1). Heterozygosity for the Z allele was associated with a variety of liver function markers including
higher alanine aminotransferase (ALT) (β=1.16 U·L−1, p=2.95×10−25), higher albumin (β=0.71 g·L−1,
p=3.11×10−229), higher alkaline phosphatase (ALP) (β=2.97 U·L−1, p=5.81×10−44), higher aspartate
aminotransferase (AST) (β=0.71 U·L−1, p=2.27×10−16) and higher direct bilirubin (β=0.041 μmol·L−1,
p=1.64×10−8). There were also strong associations with calcium (β=0.012 mmol·L−1, p=4.01×10−50),
cystatin C (0.0090 mg·L−1, p=8.91×10−12), C-reactive protein (β=−0.17 mg·L−1, p=1.11×10−6) and
insulin-like growth factor (IGF)-1 (β=−0.21 nmol·L−1, p=2.35×10−6). Heterozygotes exhibited higher sex
hormone-binding globulin (SHBG) (β=4.53 nmol·L−1, p=1.06×10−95) and testosterone (β=0.37 nmol·L−1,
p=1.84×10−57). The association with higher testosterone was driven by heterozygosity in males
(β±SE=0.76±0.045 nmol·L−1, p=3.38×10−64) but not females (β±SE=−0.030±0.0079 nmol·L−1, p=0.00015).
Z allele heterozygosity is associated with increased lung function in nonsmokers
We tested association of heterozygosity for the SERPINA1 Z allele with lung function traits in unrelated,
European UK Biobank participants with full sex, age, height, smoking status, lung function and
genotyping data (table 2). Individuals heterozygous for the Z allele exhibited higher FEV1 (β=9.26 mL,
p=0.041) but no association with FEV1/FVC or FVC compared to wild type (table 2). However, in
stratified analyses of UK Biobank never- and ever-smokers, we found that heterozygosity for the Z allele
was associated with a large increase in FEV1 (β=19.36 mL, p=9.21×10
−4) and increased FEV1/FVC
(β=0.0031, p=1.22×10−5) in never-smokers, but not in ever-smokers (table 2). The FEV1 association in
never-smokers was only slightly attenuated by including a quadratic height term in the regression
(β=18.85 mL, p=1.23×10−3). Statistical tests of Z allele*ever-smoking interactions showed interactions for
FEV1 (p=0.022) and FEV1/FVC (p=1.06×10
−4) (table S4). Furthermore, heterozygous ever-smokers
exhibited a small increased risk of COPD (both moderate–severe COPD (OR 1.16, p=0.005) and COPD
GOLD 1–4 (OR 1.12, p=0.001)), whereas heterozygous never-smokers did not (table 2).
The Z allele is strongly associated with height
Heterozygosity for the Z allele was strongly associated with height (β=1.02 cm, p=3.91×10−68) (table 2)
and, when lung function measures were not adjusted for height, the Z allele heterozygosity had much
larger effect estimates for FEV1 (β±SE=44.72±4.97 mL, p=2.20×10
−19) and FVC (β±SE=61.06±6.18 mL,
p=5.18×10−23) but not FEV1/FVC. These results suggest that carrying one copy of the Z allele confers an
advantage primarily (but not entirely) driven by increased height. To investigate the developmental stage
at which Z allele heterozygosity influences height, we tested association with height in the ALPSAC cohort
at ages 8, 15 and 24 years. The findings were consistent with Z allele heterozygosity influencing height
from adolescence and, at all the ages, directions of effect on height and lung function were consistent with
those in UK Biobank (table S5).
Sex modifies the effect of Z allele heterozygosity on lung function
We also assessed whether sex can modify the effect of the Z allele on lung function or height and found
that heterozygosity for the Z allele was associated with higher height-adjusted FEV1/FVC in females
https://doi.org/10.1183/23120541.00049-2021 4




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIGURE 1 Traits associated with the SERPINA1 Z allele in UK Biobank. Traits displayed are those with a false discovery rate (FDR) <0.01 from
phenome-wide association study of 2411 phenotypes across 379101 UK Biobank participants using the a) heterozygous model for the Z allele
(wild-type versus heterozygous individuals) and b) recessive model for the Z allele (wild-type and heterozygous individuals versus individuals
homozygous for the Z allele). HES: hospital episode statistics; FBC: full blood count; FVC: forced vital capacity; FEV1: forced expiratory volume in
1 s; PEF: peak expiratory flow; ENT: ear, nose and throat.
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(β±SE=0.0028±0.00071, p=5.89×10−5) but not in males (β±SE=−0.0015±0.0009, p=0.093) (Z allele*sex
interaction: p=0.00021 for FEV1/FVC) (tables S4 and S6).
Association between Z allele homozygosity and lung function
In contrast to the lung function-raising effects of carrying one copy of the Z allele, homozygosity for the Z
allele has been widely reported to reduce lung function and increase risk of COPD. Similarly, UK Biobank
individuals homozygous for the Z allele had significantly lower FEV1 (β=−249.21 mL, p=6.96×10−7),
FEV1/FVC (β=−0.051, p=3.54×10−16) and FVC (β=−132.16, p=0.028) compared to wild type and
heterozygous individuals, and greater risk of COPD (both moderate–severe COPD (OR 7.42,
p=5.67×10−14) and COPD GOLD 1–4 (OR 4.58, p=8.67×10−12)) (table 2). The associations between
homozygosity for the Z allele and reduced lung function and increased risk of COPD were stronger in
smokers compared to nonsmokers (table 2). Given the strength of these associations, it is interesting to
note that 58 out of 93 individuals homozygous for the Z allele did not have spirometrically defined COPD
(FEV1/FVC <0.7) and four out of 15 homozygous ever-smokers aged >60 years did not have
spirometrically defined COPD. We generated polygenic risk scores for lower FEV1/FVC by weighting
variants according to β-coefficients in the SpiroMeta consortium cohorts [19]. The 58 individuals
homozygous for the Z allele but without COPD have an average score percentile of 47.6 compared to 57.0
TABLE 1 Association between the SERPINA1 Z allele and blood biomarkers in unrelated,
European UK Biobank participants
Biomarker Heterozygous genetic model Recessive genetic model
β±SE p-value β±SE p-value
Alanine aminotransferase U·L−1 1.163±0.112 2.95×10−25 3.037±1.246 0.015
Albumin g·L−1 0.712±0.022 3.11×10−229 0.306±0.243 0.208
Alkaline phosphatase U·L−1 2.968±0.213 5.81×10−44 2.379±2.373 0.316
Apolipoprotein B g·L−1 −0.0037±0.0021 0.082 0.042±0.024 0.086
Apolipoprotein A g·L−1 −0.0045±0.0019 0.020 0.019±0.022 0.375
Aspartate aminotransferase U·L−1 0.707±0.086 2.27×10−16 6.353±0.956 3.04×10−11
C-reactive protein mg·L−1 −0.174±0.036 1.11×10−6 0.192±0.396 0.628
Calcium mmol·L−1 0.012±0.00080 4.01×10−50 0.01±0.009 0.265
Cholesterol mmol·L−1 0.0051±0.0092 0.576 0.19±0.102 0.063
Creatinine μmol·L−1 −0.067±0.129 0.601 −0.94±1.435 0.512
Cystatin C mg·L−1 0.0090±0.0013 8.91×10−12 0.019±0.015 0.204
Direct bilirubin μmol·L−1 0.041±0.0073 1.64×10−8 0.158±0.079 0.046
eGFR# −0.241±0.157 0.125 −1.810±1.732 0.296
γ-Glutamyltransferase U·L−1 0.253±0.342 0.460 8.045±3.818 0.035
Glucose mmol·L−1 −0.0032±0.010 0.758 −0.133±0.114 0.244
HbA1c mmol·mol−1 −0.187±0.052 3.40×10−4 −1.781±0.588 2.46×10−3
HDL–cholesterol mmol·L−1 0.0015±0.0030 0.605 0.142±0.033 2.01×10−5
IGF-1 nmol·L−1 −0.212±0.045 2.35×10−6 −2.245±0.5 7.19×10−6
LDL direct mmol·L−1 0.011±0.007 0.113 0.115±0.079 0.145
Lipoprotein A nmol·L−1 −0.324±0.452 0.474 −0.151±5.115 0.976
Oestradiol pmol·L−1 9.577±8.441 0.257 88.051±96.144 0.360
Phosphate mmol·L−1 0.0027±0.0013 0.042 −0.014±0.015 0.352
Rheumatoid factor IU·mL−1 0.113±0.529 0.832 −3.27±5.7 0.566
SHBG nmol·L−1 4.531±0.218 1.06×10−95 40.573±2.402 5.33×10−64
Testosterone nmol·L−1 0.37±0.023 1.84×10−57 2.986±0.258 6.96×10−31
Total bilirubin μmol·L−1 0.146±0.035 3.54×10−5 0.52±0.391 0.184
Total protein g·L−1 0.578±0.035 1.06×10−62 0.459±0.382 0.229
Triglycerides mmol·L−1 −0.023±0.0082 4.69×10−3 −0.324±0.092 4.21×10−4
Urate μmol·L−1 1.096±0.56 0.050 −1.325±6.252 0.832
Urea mmol·L−1 0.051±0.011 2.69×10−6 0.06±0.122 0.620
Vitamin D nmol·L−1 −0.041±0.175 0.816 −2.547±1.955 0.193
Results are based on linear regression adjusting for sex, age, age2, ancestry-based principal components
and genotyping array. The heterozygous or recessive genetic model was also included in the regression as
shown. eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; HDL: high-density
lipoprotein; IGF: insulin-like growth factor; LDL: low-density lipoprotein; SHBG: sex hormone-binding
globulin. #: calculated using the following formula: if cystatin C (cys)⩽0.8, then eGFR=133*((cys/0.8)
**−0.499)*(0.996**age)*[0.932 if female]; whereas if cys>0.8, then eGFR=133*((cys/0.8)**−1.328)*
(0.996**age)*[0.932 if female].
https://doi.org/10.1183/23120541.00049-2021 6
COPD | K.A. FAWCETT ET AL.
TABLE 2 Association between the SERPINA1 Z allele and height, lung function traits, and COPD in unrelated, European UK Biobank participants
Genetic
model
Smoking status Test/comparison n Height cm FEV1 mL FEV1/FVC FVC mL COPD
# COPD GOLD 1–4¶
β±SE p-value β±SE p-value β±SE p-value β±SE p-value OR (95% CI) p-value OR (95% CI) p-value
Het All 11877/291383 1.023±0.059 3.91×10−68 9.26±4.53 0.041 0.00091±0.00057 0.108 9.38±5.43 0.084 1.05 (0.96–1.14) 0.268 1.04 (0.98–1.09) 0.171
Ever-smokers 5357/133779 1.027±0.087 8.53×10−32 −2.63±7.05 0.709 −0.0017±0.00091 0.062 5.47±8.28 0.509 1.16 (1.05–1.29) 0.005 1.12 (1.04–1.20) 0.001
Never-smokers 6520/157604 1.022±0.079 3.03×10−38 19.36±5.84 9.21×10−4 0.0031±0.00071 1.22×10−5 12.77±7.15 0.074 0.87 (0.75–1.01) 0.070 0.93 (0.86–1.02) 0.113
Rec All 93/303260 1.644±0.650 0.011 −249.21±50.22 6.96×10−7 −0.051±0.0063 3.54×10−16 −132.16±60.09 0.028 7.42 (4.29–12.27) 5.67×10−14 4.58 (2.93–7.05) 8.67×10−12
Ever-smokers 35/139136 1.242±1.062 0.242 −379.21±85.54 9.30×10−6 −0.081±0.011 2.00×10−13 −177.95±100.35 0.076 9.19 (4.19–19.00) 6.27×10−9 6.13 (3.07–12.29) 2.30×10−7
Never-smokers 58/164124 1.873±0.821 0.023 −174.68±60.68 0.004 −0.034±0.0074 4.95×10−6 −107.69±74.23 0.147 5.98 (2.66–12.03) 2.69×10−6 3.68 (2.01–6.47) 1.11×10−5
Results are based on linear (or logistic, in the case of COPD) regression adjusting for sex, age, age2, ancestry-based principal components, genotyping array and, in the case of lung
function and COPD, standing height. The heterozygote (Het) or recessive (Rec) genetic model was also included in the regression as shown. FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease. #: spirometrically defined as FEV1/FVC <0.7 and FEV1<80% predicted;
















in those with COPD. This suggests that individuals homozygous for the Z allele but without COPD may
have a more protective genetic profile across other genomic loci.
Diagnosis of AATD in individuals homozygous for the Z allele
We note that only 20 out of 141 individuals who were genotyped ZZ homozygotes in the full UK Biobank
cohort had a recorded ICD-10 coding for AATD (E880) in HES. As this could indicate miscoding rather
than misdiagnosis, we investigated further in a subset of 65 homozygotes with linked primary care data.
Of these 65 ZZ homozygotes, 15 had primary care (Read) codes or ICD-10 codes for AATD and 50 did
not. Of the group without AATD codes, four had Read codes or ICD-10 codes for bronchiectasis and an
additional six had primary care (Read) codes or ICD-10 codes for COPD, indicating potential
misdiagnosis of AATD.
Discussion
We describe novel phenotypic associations of heterozygosity for the Z allele of SERPINA1 from a PheWAS
of UK Biobank, and present definitive evidence that heterozygosity for the Z allele is associated with
greater FEV1 and FEV1/FVC only in nonsmokers. Our findings have implications for individuals
heterozygous for the SERPINA1 Z allele, and more generally for the study of rare variants and
gene–environment interactions.
Our PheWAS examining the consequences of carrying one copy of the SERPINA1 Z allele revealed
potentially important associations with nonrespiratory traits and diseases. Consistent with previous reports
[12], we detected a very strong association between Z allele heterozygosity and height (with each
additional Z allele adding ∼1 cm to height). The mechanism and timing of the effect of the Z allele on
height is not understood. Our findings in the ALSPAC study suggest a possible influence of Z allele
heterozygosity on height that is manifest from puberty, although results should be interpreted with caution
given the limitations in power in ALSPAC alone. This suggests that sex hormones are a possible mediator
of the height-raising effects of the Z allele and, indeed, we detected higher levels of testosterone in
individuals heterozygous for the Z allele. However, heterozygosity for the Z allele is associated with
increased height in males and females, whereas increased testosterone was only seen in males.
Furthermore, Z allele heterozygotes also exhibit higher SHBG, suggesting that the amount of free
testosterone will be unchanged. IGF-1 levels relate to height but in our study, the magnitude of the
association was very small (<1% average levels) and it was a negative association. It is therefore still not
clear why heterozygosity and homozygosity for the Z allele is associated with increased height.
We detected strong associations between heterozygosity for the Z allele and increased risk of gall stones
and gall bladder removal. This is consistent with recent reports that the Z allele may be a risk factor for
developing gallstone disease [21, 22]. The mechanism underlying this association is unclear but previous
reports have suggested it may be related to liver dysfunction in AATD and/or the composition of bile [21, 22].
We found that individuals heterozygous for the Z allele also had increased levels of ALP, which is
characteristic of liver disease and biliary tract obstruction due to gall stones. Moreover, the Z allele is
associated with elevation of ALT and AST. Higher than normal levels of ALT and AST are hallmarks of
liver disease, and are also observed in some patients with gall bladder disease [23]. Higher bilirubin,
another potential sign of liver disease, is also exhibited by Z allele carriers. Interestingly, excess bilirubin is
thought to contribute to gall stone formation [24], so a causal pathway between the Z allele, liver
dysfunction and gall bladder problems is possible.
Heterozygosity for the Z allele was also associated with musculoskeletal phenotypes such as reduced risk of
osteoarthritis, increased risk of osteoporosis and lower bone mineral density. Calcium was increased in
heterozygotes but, as albumin was also increased, free calcium may not be different in this group. A recent
study showed that α1-antitrypsin (AAT) can inhibit receptor activator of NF-κB ligand (RANKL)-induced
osteoclast formation and bone resorption [25]. As heterozygosity for the Z allele causes reduction in AAT,
individuals heterozygous for the Z allele may have increased risk of osteoporosis and lower bone mineral
density due to increased RANKL-induced bone resorption. Lower bone mineral density has been
associated with a lower risk of osteoarthritis [26, 27].
Heterozygotes for the Z allele also had reduced risk of heart disease (even when adjusted for height) and
lower blood pressure, as well as increased risk of headache, consistent with one previous report suggesting
cluster headaches may be more frequent in heterozygotes for the Z allele [6]. There was also a marked
association between heterozygosity and reduced reticulocyte count and reticulocyte percentage, which, as
far as we are aware, has not been reported previously.
Homozygosity for the Z allele was strongly associated with self-reported/HES-recorded AATD and
respiratory traits but also haemoglobin concentration and haematocrit percentage, which may be driven by
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the associations with respiratory disease. Homozygosity was also associated with markedly higher risk of
optic neuritis and pancreatitis. These associations should be interpreted with care, especially the
association with optic neuritis, as small case numbers may have resulted in poor estimation of effect sizes.
While homozygosity for the Z allele is an established cause of respiratory disease, the effect of
heterozygosity on the respiratory health of general populations has been less clear. Our study provides
definitive data on the effects of heterozygosity for the Z allele on respiratory traits, showing that
heterozygosity is associated with greater lung function in never-smokers (even after height adjustment) but
not in smokers. Our results contrast with previous studies [8–11] that did not detect higher lung function
in participants heterozygous for the Z allele compared to wild type and with studies that did not detect
differential effects by smoking status [12]. There are several possible reasons for these discrepancies. First,
the relatively low frequency of the Z allele meant previous studies were underpowered. Our study
contained 18 times more heterozygous participants than the previous largest population-based study and
46 times more than the largest case–control study. Whilst one previous study has suggested a beneficial
effect of Z allele heterozygosity on lung function [12], it nevertheless did not detect differential effects by
smoking status. Again, this is probably due to power. Second, most of the previous studies were conducted
in current and former smokers only [8, 9, 11], and would therefore have missed the effect of Z allele
heterozygosity in nonsmokers. Third, most previous studies recruited participants based on their health
status (as in case–control studies [8, 9]) or the health status of a family member [10, 11, 28]. These
approaches can lead to ascertainment biases that might distort causal estimates. A major strength of using
the UK Biobank for our study was that participants were not ascertained based on having lung disease,
enabling a relatively unbiased assessment of the role of the heterozygosity for the Z allele in lung function.
It should be noted, however, that UK Biobank participants tend to be healthier and more highly educated
than the UK population as a whole, so detrimental effects of the Z allele may be less pronounced in UK
Biobank due to fewer lifestyle risk factors. Fourth, the Z allele is not present on most standard genotyping
arrays and therefore, high-quality imputation is required to detect its effects. Furthermore, genetic studies
tend to focus on the additive genetic model rather than heterozygous or recessive models. Because we
designed the Z allele into the UK Biobank array [17] and compared different genetic models, we were able
to robustly examine this association in UK Biobank participants.
The biological mechanism underlying the association between heterozygosity for the Z allele and increased
lung function in nonsmokers is not clear. The SERPINA1 gene encodes AAT, a glycoprotein with an
important role in inhibiting proteases, such as neutrophil elastase, which are secreted during inflammation
and cause collateral tissue damage. The Z allele produces AAT with reduced antiprotease activity and a
propensity to form polymers, which accumulate in liver, thereby reducing the circulating levels of AAT.
The polymers themselves have also been shown to be a proinflammatory stimulus in lung tissue [29],
which further perpetuates lung inflammation and damage. Homozygosity for the Z allele is the most
common cause of severe AATD, whereas heterozygosity for the Z allele has been shown to result in
intermediate levels of AAT (∼60% of normal) [30]. One might therefore expect heterozygosity to have, if
anything, a detrimental effect on lung function. There is evidence that positive selection has acted at the Z
allele locus [12, 31] and mechanisms of heterozygous advantage (through increased height [12] and
protection from infectious respiratory diseases by promotion of inflammatory responses [31]) have been
proposed. The amplification of the inflammatory response to cigarette smoke may therefore provide a
mechanism for eliminating this advantage in smokers. It has also been shown that smoking-induced
oxidative modifications to AAT reduce its ability to inhibit neutrophil elastase and turn it into a
proinflammatory mediator [32]. Cigarette smoke has been found to accelerate polymerisation of Z-type
AAT [33], suggesting a possible mechanism whereby smoking may modify the effect of the Z allele on
lung function.
We also report a novel interaction between sex and the SERPINA1 Z allele heterozygosity on FEV1/FVC.
Women heterozygous for the Z allele exhibited greater FEV1/FVC compared to wild-type, whereas men
heterozygous for the Z allele showed no significant difference to wild type. Previous studies have shown
that individuals with the fastest decline in lung function amongst AATD patients are more likely to be
male [15]. However, the reasons why sex would appear to modify the effect of Z allele heterozygosity on
lung function are not clear.
Finally, we confirm that homozygosity for the Z allele is associated with reduced lung function and
increased risk of COPD, and that these effects are exacerbated by smoking. These results are consistent
with a recently published study in UK Biobank focused on homozygosity for the Z allele [34]. Also
consistent with the work of NAKANISHI et al. [34], we show that only a minority of individuals with the ZZ
genotype have been diagnosed with AATD (as has been reported elsewhere [35, 36]), and that those
without a diagnosis of AATD, bronchiectasis or COPD have a protective genetic profile at other known
lung function loci.
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In conclusion, we have demonstrated that heterozygosity for the Z allele is associated with previously
unrecognised nonrespiratory phenotypes. Further studies will be required to confirm these findings in
independent populations; produce accurate effect estimates; and understand the causal pathways involved,
and the potential role of genetic and environmental modifiers. We have also shown that heterozygosity for
the Z allele is associated with greater lung function in nonsmokers. Our results demonstrate that large
sample sizes are required to study the effects of rare variants, particularly when these effects depend on an
environmental stimulus. The opposing directions of effect of Z allele heterozygosity and homozygosity on
lung function demonstrate that the additive genetic model is not always appropriate for genetic studies of
rarer variants such as the SERPINA1 Z allele. Our findings suggest that while individuals who are
heterozygous for the Z allele may not exhibit symptoms of AATD, they may be more susceptible to
smoking-induced lung disease and have altered risk of other nonrespiratory conditions.
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